This is a preview of subscription content, log in via an institution to check access.
Notes
In Canada, tofacitinib is available by prescription for the treatment of inflammatory diseases (e.g. rheumatoid arthritis, psoriatic arthritis, ulcerative colitis) when other therapies do not work. Ruxolitinib is also available by prescription for the treatment of certain rare blood cancers (e.g. primary myelofibrosis and polycythaemia vera).
Reference
Health Canada. Summary Safety Review - Xeljanz and Xeljanz XR (tofacitinib), and Jakavi (ruxolitinib) - Janus Kinase (JAK) inhibitors - Health Canada. Internet Document : 18 Jun 2020. Available from: URL: https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&linkID=SSR00240
Rights and permissions
About this article
Cite this article
Health Canada: risk of VTE with tofacitinib and ruxolitinib. Reactions Weekly 1811, 3 (2020). https://doi.org/10.1007/s40278-020-80226-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-80226-2